iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 04/08/2025

1) Japanese researchers are recruiting ME/CFS patients for a new randomised trial of Rituximab, a monoclonal antibody that targets the CD20 protein found on B-cells. This is a bit surprising because the Norwegian phase-3 trial of Rituximab had negative results for ME/CFS.

43914 0

ME/CFS Science @mecfsscience.org · 04/08/2025

2) The Japanese group seems to be aware of that. In a press release they say their trial will get a better view of clinical responses by using a different outcome measure and "by having daily symptoms recorded with an app stored on a smartphone." www.ncnp.go.jp/topic...

1100 0

ME/CFS Science @mecfsscience.org · 04/08/2025

3) The trial will be a placebo-controlled, double-blind study with a cross-over design, meaning that all patients will eventually get the drug. They plan to recruit 30 patients using the Canadian Consensus criteria for ME/CFS.

190 0